Emily K. Horn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emily K. Horn has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Johnna Perdrizet
Global Value and Evidence, Pfizer Canada, Kirkland, Canada
7 shared publications - Matt Wasserman
Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA
5 shared publications - Elizabeth Holdsworth La
GSK , Philadelphia, Pennsylvania
4 shared publications Katherine Theiss-Nyland
4 shared publicationsSusan I. Gerber
4 shared publicationsAlison Kawai
RTI Health Solutions, Durham, United States
3 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Vaccine profile of adjuvanted RSVPreF3 in adults: prevention of RSV-related lower respiratory tract disease and emerging evidence of potential cardiovascular and respiratory benefits
- 16 November 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Open AccessVaccine profile of adjuvanted RSVPreF3 in adults: prevention of RSV-related lower respiratory tract disease and emerging evidence of potential cardiovascular and respiratory benefits
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , OA2271
Late Breaking Abstract - Adjuvanted RSVPreF3 vaccine effectiveness against cardiovascular events and disease exacerbations (2023–2025)
Introduction: Research suggests that the adjuvanted RSVPreF3 vaccine is effective in reducing risk of major adverse cardiovascular events (MACE) and severe exacerbations of chronic obstructive pulmonary disease (COPD) and asthma over one respiratory syncytial virus (RSV) season (Singer et al. Presented at ReSViNET 2026). The present study evaluated vaccine effectiveness (VE) over two RSV seasons. Methods: A retrospective cohort study among adults ≥60 years of age (YOA) in the US was conducted using claims data (Optum Research Database, Aug 2022–May 2025). Vaccinated and unvaccinated adults were exact matched on key baseline characteristics, with remaining differences balanced using propensity score weighting. Hazard ratios (HRs) comparing risk of overall and RSV-related MACE and COPD and asthma exacerbations in adults at increased risk for severe RSV disease were estimated using Cox proportional hazards models (VE = [1 − HR] × 100%). Results: The full analysis included 662,982 vaccinated and 2,651,928 unvaccinated adults (median follow-up: 16.4 and 14.3 months, respectively). VE against RSV-related outcomes was 58.5% (95% confidence interval: 46.0–68.1%) for MACE, 57.6% (46.1–66.7%) for severe COPD exacerbations, and 57.3% (22.3–76.6%) for severe asthma exacerbations (Fig 1). erj;68/suppl_70/OA2271/F1 F1 F1 Conclusions: Adjuvanted RSVPreF3 vaccination was associated with lower risk of RSV-related MACE and respiratory exacerbations over two RSV seasons in US adults ≥60 YOA. Results may inform future recommendations in revaccination timing.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , OA2271
Late Breaking Abstract - Adjuvanted RSVPreF3 vaccine effectiveness against cardiovascular events and disease exacerbations (2023–2025)
Introduction: Research suggests that the adjuvanted RSVPreF3 vaccine is effective in reducing risk of major adverse cardiovascular events (MACE) and severe exacerbations of chronic obstructive pulmonary disease (COPD) and asthma over one respiratory syncytial virus (RSV) season (Singer et al. Presented at ReSViNET 2026). The present study evaluated vaccine effectiveness (VE) over two RSV seasons. Methods: A retrospective cohort study among adults ≥60 years of age (YOA) in the US was conducted using claims data (Optum Research Database, Aug 2022–May 2025). Vaccinated and unvaccinated adults were exact matched on key baseline characteristics, with remaining differences balanced using propensity score weighting. Hazard ratios (HRs) comparing risk of overall and RSV-related MACE and COPD and asthma exacerbations in adults at increased risk for severe RSV disease were estimated using Cox proportional hazards models (VE = [1 − HR] × 100%). Results: The full analysis included 662,982 vaccinated and 2,651,928 unvaccinated adults (median follow-up: 16.4 and 14.3 months, respectively). VE against RSV-related outcomes was 58.5% (95% confidence interval: 46.0–68.1%) for MACE, 57.6% (46.1–66.7%) for severe COPD exacerbations, and 57.3% (22.3–76.6%) for severe asthma exacerbations (Fig 1). erj;68/suppl_70/OA2271/F1 F1 F1 Conclusions: Adjuvanted RSVPreF3 vaccination was associated with lower risk of RSV-related MACE and respiratory exacerbations over two RSV seasons in US adults ≥60 YOA. Results may inform future recommendations in revaccination timing.
- Open Access
- 30 November 2025
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 19 (12) , e70181
Prevalence and Age at Diagnosis of Risk Factors for Severe Respiratory Syncytial Virus Disease Among US Adults: An Analysis of 2011–2020 NHANES Data
Background: Respiratory syncytial virus (RSV) vaccines are approved in the United States (US) among adults ≥ 60 years of age (YoA). Understanding disparities in risk factors (RFs) for severe RSV disease by social determinants of health is crucial for equitable RSV vaccination among at‐risk adults. We investigated diagnosed/undiagnosed RF prevalence, age at RF diagnosis/identification, and association of key characteristics with RF diagnosis/identification among US adults. Methods: We analyzed 2011–2020 National Health and Nutrition Examination Survey (NHANES) data to calculate RF prevalence and mean age at RF diagnosis/identification. Multivariable regression models were developed to estimate associations between characteristics and RF diagnosis/identification. Results were weighted to reflect the US noninstitutionalized adult population ≥ 20 YoA. Results: After weighting, the analysis included a sample of 233,118,491 adults. Overall, 28.0% had ≥ 1 diagnosed RF (12.8% pulmonary; 9.2% cardiovascular; 14.1% endocrine/metabolic). Undiagnosed diabetes and renal disease were identified in 3.7% and 12.5% of adults, respectively. Among those with ≥ 1 diagnosed RF, mean age at RF diagnosis was 40.1 years and 60.0% were diagnosed before 50 YoA. Increasing age, belonging to a racial or ethnic minority group, and lower income were significantly associated with having ≥ 1 RF. Conclusions: Approximately one in four adults had ≥ 1 diagnosed RF for RSV, with most diagnosed before 50 YoA. Adults in racial and ethnic minority and socioeconomically disadvantaged groups were more likely to have RFs and be diagnosed at younger ages. Efforts are needed to ensure all US adults at increased risk for severe RSV disease have access to RSV vaccination.
- 30 November 2025
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 19 (12) , e70181
Open AccessPrevalence and Age at Diagnosis of Risk Factors for Severe Respiratory Syncytial Virus Disease Among US Adults: An Analysis of 2011–2020 NHANES Data
Background: Respiratory syncytial virus (RSV) vaccines are approved in the United States (US) among adults ≥ 60 years of age (YoA). Understanding disparities in risk factors (RFs) for severe RSV disease by social determinants of health is crucial for equitable RSV vaccination among at‐risk adults. We investigated diagnosed/undiagnosed RF prevalence, age at RF diagnosis/identification, and association of key characteristics with RF diagnosis/identification among US adults. Methods: We analyzed 2011–2020 National Health and Nutrition Examination Survey (NHANES) data to calculate RF prevalence and mean age at RF diagnosis/identification. Multivariable regression models were developed to estimate associations between characteristics and RF diagnosis/identification. Results were weighted to reflect the US noninstitutionalized adult population ≥ 20 YoA. Results: After weighting, the analysis included a sample of 233,118,491 adults. Overall, 28.0% had ≥ 1 diagnosed RF (12.8% pulmonary; 9.2% cardiovascular; 14.1% endocrine/metabolic). Undiagnosed diabetes and renal disease were identified in 3.7% and 12.5% of adults, respectively. Among those with ≥ 1 diagnosed RF, mean age at RF diagnosis was 40.1 years and 60.0% were diagnosed before 50 YoA. Increasing age, belonging to a racial or ethnic minority group, and lower income were significantly associated with having ≥ 1 RF. Conclusions: Approximately one in four adults had ≥ 1 diagnosed RF for RSV, with most diagnosed before 50 YoA. Adults in racial and ethnic minority and socioeconomically disadvantaged groups were more likely to have RFs and be diagnosed at younger ages. Efforts are needed to ensure all US adults at increased risk for severe RSV disease have access to RSV vaccination.
- Open Access
- 31 August 2025
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (10) , 2321-2340
RSV Testing Patterns and Characteristics Associated with RSV Testing Among Adults Aged 50 Years or Older in the United States
Introduction Respiratory syncytial virus (RSV) is a common respiratory virus that can cause severe disease, particularly in older adults and adults with underlying medical conditions. However, RSV infections often go underdiagnosed due to infrequent testing and assay sensitivity limitations. To better understand RSV epidemiology and disease burden, we investigated respiratory virus testing patterns and characteristics associated with RSV testing among United States (US) adults aged ≥ 50 years with acute respiratory illnesses (ARIs). Methods This was a retrospective study using Optum® electronic health records data from 2015 to 2023. Medically-attended ARIs were identified among adults aged ≥ 50 years; percentages of ARIs tested for RSV and other respiratory viruses were calculated and stratified by epidemiological year (EY) and most intensive care setting during the ARI episode. Patient, provider, and ARI characteristics associated with the likelihood of RSV testing were assessed using multivariable logistic regression models. Results Among 22,475,891 included ARIs, RSV testing occurred in 2.4% (n = 530,452) of episodes. RSV testing increased over time (1.3–5.9% from 2016–2017 to 2022–2023 EYs), though it remained markedly lower than influenza (5.8–15.1%; 2016–2017 to 2022–2023 EYs) and SARS-CoV-2 (5.8–22.6%; 2019–2020 to 2022–2023 EYs) testing. By most intensive level of care received, RSV testing from 2016–2023 was more frequent in inpatient (9.5–27.5%) and emergency department (ED; 1.4–17.9%) settings than the outpatient setting (0.3–1.4%). Among included covariates in adjusted analyses, most intensive care setting [ED: 9.3-fold, inpatient: 31.2-fold (versus outpatient)] and healthcare organization (0.02–13.8-fold) were most significantly associated with likelihood of RSV testing. Conclusion The likelihood of RSV testing varied significantly by most intensive care setting and healthcare organization. Despite increasing RSV testing over time, RSV remains infrequently tested among US adults. Under-detection of medically-attended RSV cases should be accounted for when estimating RSV disease burden and the potential impact of RSV prevention strategies. A Graphical Abstract is available for this article. Graphical Abstract
- 31 August 2025
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (10) , 2321-2340
Open AccessRSV Testing Patterns and Characteristics Associated with RSV Testing Among Adults Aged 50 Years or Older in the United States
Introduction Respiratory syncytial virus (RSV) is a common respiratory virus that can cause severe disease, particularly in older adults and adults with underlying medical conditions. However, RSV infections often go underdiagnosed due to infrequent testing and assay sensitivity limitations. To better understand RSV epidemiology and disease burden, we investigated respiratory virus testing patterns and characteristics associated with RSV testing among United States (US) adults aged ≥ 50 years with acute respiratory illnesses (ARIs). Methods This was a retrospective study using Optum® electronic health records data from 2015 to 2023. Medically-attended ARIs were identified among adults aged ≥ 50 years; percentages of ARIs tested for RSV and other respiratory viruses were calculated and stratified by epidemiological year (EY) and most intensive care setting during the ARI episode. Patient, provider, and ARI characteristics associated with the likelihood of RSV testing were assessed using multivariable logistic regression models. Results Among 22,475,891 included ARIs, RSV testing occurred in 2.4% (n = 530,452) of episodes. RSV testing increased over time (1.3–5.9% from 2016–2017 to 2022–2023 EYs), though it remained markedly lower than influenza (5.8–15.1%; 2016–2017 to 2022–2023 EYs) and SARS-CoV-2 (5.8–22.6%; 2019–2020 to 2022–2023 EYs) testing. By most intensive level of care received, RSV testing from 2016–2023 was more frequent in inpatient (9.5–27.5%) and emergency department (ED; 1.4–17.9%) settings than the outpatient setting (0.3–1.4%). Among included covariates in adjusted analyses, most intensive care setting [ED: 9.3-fold, inpatient: 31.2-fold (versus outpatient)] and healthcare organization (0.02–13.8-fold) were most significantly associated with likelihood of RSV testing. Conclusion The likelihood of RSV testing varied significantly by most intensive care setting and healthcare organization. Despite increasing RSV testing over time, RSV remains infrequently tested among US adults. Under-detection of medically-attended RSV cases should be accounted for when estimating RSV disease burden and the potential impact of RSV prevention strategies. A Graphical Abstract is available for this article. Graphical Abstract
- Open Access
- 24 December 2024
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (4) , 459-471
Disparities in Respiratory Syncytial Virus Risk Factors, Diagnosis, and Outcomes in Adults by Race, Ethnicity, and Other Social Determinants of Health in the United States
Respiratory syncytial virus (RSV) vaccination could improve health equity by protecting individuals who are disproportionally at increased risk of RSV infection and severe RSV-related outcomes. However, limited information is available about RSV-related disparities among United States (US) adults. We reviewed US-specific literature regarding disparities across adult populations in having risk factors for severe RSV disease (cardiopulmonary disease, diabetes, liver disease, kidney disease). We summarize available evidence regarding disparities in having or being diagnosed with RSV, as well as experiencing severe RSV-related health outcomes. Disparities are analyzed by race, ethnicity, socioeconomic status, and other social determinants of health. RSV-related disparities are observed across all outcomes of interest, although RSV-specific data are limited in some cases. Racial and ethnic minority groups and socioeconomically disadvantaged populations are more likely to have risk factors for severe RSV disease, overall and at younger ages, yet individuals from these groups are more often underdiagnosed. Disparities in RSV-related hospitalizations, emergency department visits, and deaths are observed, especially among adults from racial and ethnic minority groups, of lower socioeconomic status, and in poorer or more crowded neighborhoods. Findings highlight the importance of RSV vaccination among these groups to improve health equity.
- 24 December 2024
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (4) , 459-471
Open AccessDisparities in Respiratory Syncytial Virus Risk Factors, Diagnosis, and Outcomes in Adults by Race, Ethnicity, and Other Social Determinants of Health in the United States
Respiratory syncytial virus (RSV) vaccination could improve health equity by protecting individuals who are disproportionally at increased risk of RSV infection and severe RSV-related outcomes. However, limited information is available about RSV-related disparities among United States (US) adults. We reviewed US-specific literature regarding disparities across adult populations in having risk factors for severe RSV disease (cardiopulmonary disease, diabetes, liver disease, kidney disease). We summarize available evidence regarding disparities in having or being diagnosed with RSV, as well as experiencing severe RSV-related health outcomes. Disparities are analyzed by race, ethnicity, socioeconomic status, and other social determinants of health. RSV-related disparities are observed across all outcomes of interest, although RSV-specific data are limited in some cases. Racial and ethnic minority groups and socioeconomically disadvantaged populations are more likely to have risk factors for severe RSV disease, overall and at younger ages, yet individuals from these groups are more often underdiagnosed. Disparities in RSV-related hospitalizations, emergency department visits, and deaths are observed, especially among adults from racial and ethnic minority groups, of lower socioeconomic status, and in poorer or more crowded neighborhoods. Findings highlight the importance of RSV vaccination among these groups to improve health equity.
- 12 March 2024
- Published by Elsevier in The Journal for Nurse Practitioners
- Vol. 20 (5)
Nurse Practitioners’ Knowledge, Attitudes, and Practices Surrounding Adult Hepatitis Vaccination
- 12 March 2024
- Published by Elsevier in The Journal for Nurse Practitioners
- Vol. 20 (5)
Nurse Practitioners’ Knowledge, Attitudes, and Practices Surrounding Adult Hepatitis Vaccination
- Open Access
- 28 February 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (1) , e199-e218
The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies
Background: Hepatitis A (HepA) vaccines are recommended for US adults at risk of HepA. Ongoing United States (US) HepA outbreaks since 2016 have primarily spread person-to-person, especially among at-risk groups. We investigated the health outcomes, economic burden, and outbreak management considerations associated with HepA outbreaks from 2016 onwards. Methods: A systematic literature review was conducted to assess HepA outbreak-associated health outcomes, health care resource utilization (HCRU), and economic burden. A targeted literature review evaluated HepA outbreak management considerations. Results: Across 33 studies reporting on HepA outbreak-associated health outcomes/HCRU, frequently reported HepA-related morbidities included acute liver failure/injury (n = 6 studies of 33 studies) and liver transplantation (n = 5 of 33); reported case fatality rates ranged from 0% to 10.8%. Hospitalization rates reported in studies investigating person-to-person outbreaks ranged from 41.6% to 84.8%. Ten studies reported on outbreak-associated economic burden, with a national study reporting an average cost of over $16 000 per hospitalization. Thirty-four studies reported on outbreak management; challenges included difficulty reaching at-risk groups and vaccination distrust. Successes included targeted interventions and increasing public awareness. Conclusions: This review indicates a considerable clinical and economic burden of ongoing US HepA outbreaks. Targeted prevention strategies and increased public awareness and vaccination coverage are needed to reduce HepA burden and prevent future outbreaks.
- 28 February 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (1) , e199-e218
Open AccessThe Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies
Background: Hepatitis A (HepA) vaccines are recommended for US adults at risk of HepA. Ongoing United States (US) HepA outbreaks since 2016 have primarily spread person-to-person, especially among at-risk groups. We investigated the health outcomes, economic burden, and outbreak management considerations associated with HepA outbreaks from 2016 onwards. Methods: A systematic literature review was conducted to assess HepA outbreak-associated health outcomes, health care resource utilization (HCRU), and economic burden. A targeted literature review evaluated HepA outbreak management considerations. Results: Across 33 studies reporting on HepA outbreak-associated health outcomes/HCRU, frequently reported HepA-related morbidities included acute liver failure/injury (n = 6 studies of 33 studies) and liver transplantation (n = 5 of 33); reported case fatality rates ranged from 0% to 10.8%. Hospitalization rates reported in studies investigating person-to-person outbreaks ranged from 41.6% to 84.8%. Ten studies reported on outbreak-associated economic burden, with a national study reporting an average cost of over $16 000 per hospitalization. Thirty-four studies reported on outbreak management; challenges included difficulty reaching at-risk groups and vaccination distrust. Successes included targeted interventions and increasing public awareness. Conclusions: This review indicates a considerable clinical and economic burden of ongoing US HepA outbreaks. Targeted prevention strategies and increased public awareness and vaccination coverage are needed to reduce HepA burden and prevent future outbreaks.
- Open Access
- 16 May 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 11 (4) , 1-3
Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
- 16 May 2022
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 11 (4) , 1-3
Open AccessResponse to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”